Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

by Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman
Published 2016-06-01

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

by Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S. Olivo, James Song, Corina E. Dutcus, Peter A. Kaufman
Published 2016-01-01

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

by Chris Twelves, Sue Cheeseman, Will Sopwith, Matthew Thompson, Majid Riaz, Necibe Ahat-Donker, Melissa Myland, Adam Lee, Raymond Przybysz, Stuart Turner, Geoff Hall, Tim Perren
Published 2020-01-01

CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

by Rob Coleman, Janet Brown, Emma Rathbone, Louise Flanagan, Amber Reid, Jessica Kendall, Sacha Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Sarah Brown
Published 2020-01-01

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.

by Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, Louise Hiller, Anne-Laure Vallier, Susan Ingle, Richard Hardy, Sarah J Bowden, Janet A Dunn, Chris Twelves, Christopher J Poole, Carlos Caldas, Helena M Earl, Paul D P Pharoah, Jean E Abraham
Published 2016-01-01